Betalin Therapeutics
Ramat Gan
About Betalin Therapeutics
Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.8M
- Last round: Series Unknown (Jan 2022)
- Website: betalintherapeutics.com
- Phone: +972779400370
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/betalin-therapeutics-66923 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.